JP2019529442A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529442A5
JP2019529442A5 JP2019515433A JP2019515433A JP2019529442A5 JP 2019529442 A5 JP2019529442 A5 JP 2019529442A5 JP 2019515433 A JP2019515433 A JP 2019515433A JP 2019515433 A JP2019515433 A JP 2019515433A JP 2019529442 A5 JP2019529442 A5 JP 2019529442A5
Authority
JP
Japan
Prior art keywords
mmol
conjugate
composition
composition according
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019515433A
Other languages
English (en)
Japanese (ja)
Other versions
JP7160799B2 (ja
JP2019529442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/073983 external-priority patent/WO2018055070A1/en
Publication of JP2019529442A publication Critical patent/JP2019529442A/ja
Publication of JP2019529442A5 publication Critical patent/JP2019529442A5/ja
Application granted granted Critical
Publication of JP7160799B2 publication Critical patent/JP7160799B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019515433A 2016-09-23 2017-09-22 タペンタドールの非経口投与用安定製剤 Active JP7160799B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16190255.6 2016-09-23
EP16190255 2016-09-23
PCT/EP2017/073983 WO2018055070A1 (en) 2016-09-23 2017-09-22 Stable formulation for parenteral administration of tapentadol

Publications (3)

Publication Number Publication Date
JP2019529442A JP2019529442A (ja) 2019-10-17
JP2019529442A5 true JP2019529442A5 (enExample) 2020-10-22
JP7160799B2 JP7160799B2 (ja) 2022-10-25

Family

ID=56997349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019515433A Active JP7160799B2 (ja) 2016-09-23 2017-09-22 タペンタドールの非経口投与用安定製剤

Country Status (17)

Country Link
US (1) US10898452B2 (enExample)
EP (1) EP3515412B1 (enExample)
JP (1) JP7160799B2 (enExample)
KR (1) KR20190057349A (enExample)
CN (1) CN109996533A (enExample)
AU (1) AU2017329964B2 (enExample)
BR (1) BR112019005439A2 (enExample)
CA (1) CA3037810A1 (enExample)
CL (1) CL2019000690A1 (enExample)
CO (1) CO2019002557A2 (enExample)
EA (1) EA201990744A1 (enExample)
EC (1) ECSP19019253A (enExample)
ES (1) ES3027562T3 (enExample)
IL (1) IL265477A (enExample)
MX (1) MX2019003257A (enExample)
PE (1) PE20190908A1 (enExample)
WO (1) WO2018055070A1 (enExample)

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334422D0 (en) 1983-12-23 1984-02-01 Sterwin Ag Composition
GB8334423D0 (en) 1983-12-23 1984-02-01 Sterwin Ag Composition
US4775678A (en) 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
CA2013755C (en) 1989-04-05 1993-11-30 Simon Benita Medicinal emulsions
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
US6183758B1 (en) 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6211169B1 (en) 1999-09-29 2001-04-03 Aesgen, Inc. Stable calcitriol solution for packaging into vials
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
DE10112325A1 (de) 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols
JP4905616B2 (ja) 2001-04-19 2012-03-28 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
FR2832063B1 (fr) 2001-11-15 2004-08-27 Aguettant Lab Procede de production de solutions stables de substances phenoliques et les solutions en resultant
JP2005526079A (ja) 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20040101563A1 (en) 2002-07-18 2004-05-27 Kundu Subhas C. Storage stable antihistaminic syrup formulations
RU2359698C2 (ru) 2002-09-13 2009-06-27 Сайдекс, Инк. Капсулы, содержащие водные наполняющие композиции, стабилизированные производным циклодекстрина
US6888993B2 (en) 2002-11-27 2005-05-03 Corning Incorporated Dispersion compensating optical fiber for SMF and transmission link including same
ITMI20022748A1 (it) 2002-12-23 2004-06-24 Eurand Int Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione.
EP1599222B1 (en) 2003-01-08 2009-03-04 Novartis Vaccines and Diagnostics, Inc. Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
JP2007538091A (ja) 2004-05-17 2007-12-27 ファーマコフォア・インコーポレイテッド 痛みを処置または予防するための組成物および方法
SI1612203T1 (sl) 2004-06-28 2007-12-31 Gruenenthal Chemie Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
KR101204657B1 (ko) 2004-07-01 2012-11-27 그뤼넨탈 게엠베하 (1r,2r)-3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀을 함유하는 남용 방지 경구 투여 제형
DE102004032103A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20110098284A1 (en) 2005-04-28 2011-04-28 Najib Babul Methods and compositions for treating pain
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
EP2010145A2 (en) 2006-04-25 2009-01-07 Croda, Inc. Modification of percutaneous absorption of topically active materials
PL2012763T3 (pl) 2006-04-28 2011-08-31 Gruenenthal Gmbh Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenol i NSAID
WO2007128413A1 (en) 2006-04-28 2007-11-15 Grünenthal GmbH Pharmaceutical combination comprising 3- ( 3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
KR101370398B1 (ko) 2006-07-24 2014-03-05 얀센 파마슈티카 엔.브이. (２ｒ,３ｒ)-３-(３-메톡시페닐)-ｎ,ｎ,２-트리메틸펜탄아민의 제조방법
EP1905440A1 (de) 2006-09-06 2008-04-02 Boehringer Ingelheim Pharma GmbH & Co. KG Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
JP2008266168A (ja) 2007-04-18 2008-11-06 Teika Seiyaku Kk 眼科用剤
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
EP1992334A1 (en) 2007-05-08 2008-11-19 Docpharma NV/SA Storage-stable formulation of oxidation-sensitive phenolic drug, especially paracetamol, comprises aqueous drug solution deoxygenated by a temperature-controlled manufacturing process of the formulation
CN102065852B (zh) * 2007-11-23 2015-06-17 格吕伦塔尔有限公司 他喷他多组合物
JP2011506342A (ja) 2007-12-06 2011-03-03 ペイン セラピューティクス インコーポレイテッド 微粉化オピオイド組成物、製剤および剤形、ならびにそれらの製造方法
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
WO2009124586A1 (en) 2008-04-08 2009-10-15 Arpida Ag Aqueous pharmaceutical formulation
NZ592437A (en) 2008-10-30 2013-03-28 Gruenenthal Chemie A dosage form comprising tapentadol and an opioid antagonist
MX2011007399A (es) 2009-01-09 2011-11-18 Panacea Biotec Ltd Suspension farmaceutica de liberacion doble.
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
EP2246044A1 (en) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
WO2011016487A1 (ja) 2009-08-05 2011-02-10 ナガセ医薬品株式会社 インジゴカルミン製剤
WO2011071400A1 (en) 2009-12-10 2011-06-16 Tecnimede - Sociedade Técnico-Medicinal, S.A. Method and composition for preparing stable liquid formulations of paracetamol
US20110190267A1 (en) 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
MX2012011355A (es) 2010-03-30 2012-11-30 Phosphagenics Ltd Parche de suministro transdermico.
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
EA024193B1 (ru) * 2011-03-04 2016-08-31 Грюненталь Гмбх Фармацевтическая композиция на водной основе, предназначенная для парентерального введения тапентадола
MX369121B (es) * 2011-03-04 2019-10-30 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral.
MX374468B (es) 2011-03-04 2025-03-06 Gruenenthal Gmbh Composicion farmaceutica acuosa semisolida que contiene tapentadol.
US20150073000A1 (en) 2012-03-27 2015-03-12 Fresenius Kabi Oncology Limited Stable ready-to-use pharmaceutical composition of pemetrexed
CN103159633B (zh) 2012-07-06 2015-08-12 江苏恩华药业股份有限公司 他喷他多的制备方法及用于制备他喷他多的化合物
JP6360488B2 (ja) 2012-11-01 2018-07-18 トレント・ファーマシューティカルズ・リミテッドＴｏｒｒｅｎｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｉｍｉｔｅｄ 非経口投与のためのタペンタドールの薬学的組成物
AU2014230834B9 (en) 2013-03-14 2017-08-31 Fresenius Kabi Deutschland Gmbh Injectable morphine formulations
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
CN103735550B (zh) 2013-12-25 2015-11-18 上海市闸北区中心医院 一种治疗慢性肾脏病心肌损伤的药物组合物及其应用
CN103735500B (zh) 2014-01-28 2016-01-20 江苏华泽医药科技有限公司 盐酸他喷他多注射液及其制备方法
EA036258B1 (ru) * 2015-03-27 2020-10-20 Грюненталь Гмбх Стабильный препарат для парентерального введения тапентадола
EP3585370A1 (en) * 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic

Similar Documents

Publication Publication Date Title
HRP20171256T1 (hr) Farmaceutski pripravci karbetocina
CN102038648B (zh) 治疗消化性溃疡的粉针剂及其制备方法
WO2013089394A3 (ko) 고분자 나노입자 수용액 조성물 및 그 제조방법
JP2011201907A5 (enExample)
JP2014530801A5 (enExample)
HRP20191477T1 (hr) Farmaceutski sastav s-ketamin hidroklorida
ME02459B (me) Rastvor za oralno ordiniranje
RU2012113844A (ru) Пероральные суспензионные лекарственные формы ацетата эсликарбазепина
HRP20201696T1 (hr) Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu
HRP20200196T1 (hr) Fiziološki balansirane injektabilne formulacije fosnetupitanta
JPWO2015190378A1 (ja) 安定なアダリムマブ水性製剤
RU2019119405A (ru) Лиофилизированные фармацевтические композиции далбаванцина
RU2013128357A (ru) Стабильный готовый к применению инъекционный раствор цетрореликса
RU2014114512A (ru) Водные композиции, содержащие арбекацин
EA201792144A1 (ru) Стабильный препарат для парентерального введения тапентадола
JP2018039810A5 (enExample)
CN105919931B (zh) 一种稳定的盐酸法舒地尔注射液及其制备方法
JP2019529442A5 (enExample)
WO2006131923A3 (en) Novel salts of conjugated psychotropic drugs and processes of preparing same
FI4000628T3 (fi) Koostumus ja menetelmä vankomysiinin oraaliselle nesteelle
WO2021216450A8 (en) Opioid antagonist formulations
WO2010068181A8 (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
ITRM990483A1 (it) Composizione per la prevenzione e cura delle disfunzioni e patologie renali di tipo tossico e funzionale.
WO2004093867A3 (en) Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use
RU2011134414A (ru) Комбинация фульвовой кислоты для лечения различных состояний и болезней